AB Science Past Earnings Performance

Past criteria checks 0/6

AB Science has been growing earnings at an average annual rate of 15.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 12.7% per year.

Key information

15.5%

Earnings growth rate

21.7%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-12.7%
Return on equityn/a
Net Margin-558.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AB Science makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ABSC.F Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-636
31 Mar 241-938
31 Dec 231-12410
30 Sep 231-14311
30 Jun 231-17312
31 Mar 231-15313
31 Dec 221-14413
30 Sep 221-15414
30 Jun 221-17414
31 Mar 222-16413
31 Dec 212-14411
30 Sep 212-13412
30 Jun 212-11312
31 Mar 212-13312
31 Dec 202-15313
30 Sep 202-16312
30 Jun 202-18312
31 Mar 202-20314
31 Dec 192-22316
30 Sep 192-25319
30 Jun 192-28323
31 Mar 192-27325
31 Dec 182-26327
30 Sep 182-25327
30 Jun 182-25327
31 Mar 182-26327
31 Dec 172-27327
30 Sep 172-27326
30 Jun 172-26326
31 Mar 172-27327
31 Dec 162-28328
30 Sep 162-28427
30 Jun 162-28427
31 Mar 162-28425
31 Dec 152-27424
30 Sep 152-24421
30 Jun 152-22419
31 Mar 152-19416
31 Dec 142-16413
30 Sep 142-16413
30 Jun 142-15313
31 Mar 142-15312
31 Dec 132-15312

Quality Earnings: ABSC.F is currently unprofitable.

Growing Profit Margin: ABSC.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ABSC.F is unprofitable, but has reduced losses over the past 5 years at a rate of 15.5% per year.

Accelerating Growth: Unable to compare ABSC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABSC.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: ABSC.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 17:21
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AB Science S.A. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark van der GeestABN AMRO Bank N.V.
Michael RyskinBofA Global Research
Swayampakula RamakanthH.C. Wainwright & Co.